WO2025126157 - ANTI-IL-1RAP BINDING DOMAINS AND ANTIBODY-DRUG CONJUGATES THEREOF
National phase entry is expected:
Publication Number
WO/2025/126157
Publication Date
19.06.2025
International Application No.
PCT/IB2024/062667
International Filing Date
13.12.2024
Title **
[English]
ANTI-IL-1RAP BINDING DOMAINS AND ANTIBODY-DRUG CONJUGATES THEREOF
[French]
DOMAINES DE LIAISON ANTI-IL-1RAP ET CONJUGUÉS ANTICORPS-MÉDICAMENT ASSOCIÉS
Applicants **
ADVESYA
Inventors
SAINSON, Richard Charles Alfred
AUPEPIN DE LAMOTHE-DREUZY, Edouard
FAVRE-BULLE, Olivier
COLLETTE, Alexis
Priority Data
63/610,670
15.12.2023
US
63/641,123
01.05.2024
US
63/706,373
11.10.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5753 | |
| EPO | Filing, Examination, Granting | 73260 | |
| Japan | Filing, Examination, Granting | 4223 | |
| South Korea | Filing, Examination, Granting | 6350 | |
| USA | Filing, Examination, Granting | 26140 |
Total:
115,726
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure is directed to antibody drug conjugates (ADCs) comprising an antibody or antigen binding fragment thereof that binds IL-1RAP. The ADCs of the present disclosure are useful for, among other things, treating diseases with upregulated IL-1RAP expression.[French]
La présente invention concerne des conjugués anticorps-médicament (ADC) comprenant un anticorps ou un fragment de liaison à l'antigène de celui-ci qui se lie à IL-1RAP. Les ADC de la présente invention sont utiles, entre autres, pour traiter des maladies avec une expression d'IL-1RAP régulée à la hausse.